HK inno.N (195940) Fundamentals 2026 — P/E 12.5x, Revenue Analysis | SniperIQ
HK inno.N (195940) is a KR-listed Healthcare company in Medical - Care Facilities with a market capitalization of ₩1.06T, trading at ₩37300.00 on the KOE. This SniperIQ fundamentals page covers HK inno.N's valuation (P/E 12.5x, P/B 0.8x), profitability (net margin 7.8%), revenue (₩1.06T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is HK inno.N's market cap?
HK inno.N (195940) has a market capitalization of approximately ₩1.06T, trading at ₩37300.00 on the KOE. Market cap moves with the live share price.
What is HK inno.N's P/E ratio?
HK inno.N's trailing twelve-month P/E ratio is 12.5x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is HK inno.N?
HK inno.N runs a net profit margin of 7.8%, a gross margin of 44.9%, and an operating margin of 11.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does HK inno.N generate?
HK inno.N reported revenue of ₩1.06T for fiscal year 2025, with net income of ₩75.7B and earnings per share (EPS) of 2672.09. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does HK inno.N pay a dividend?
HK inno.N offers a trailing dividend yield of about 1.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is HK inno.N financially healthy?
HK inno.N carries a debt-to-equity ratio of 0.38x and a current ratio of 0.83x, with a market beta of 0.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is HK inno.N a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HK inno.N (195940) the key facts are: market cap ₩1.06T, P/E 12.5x, revenue ₩1.06T, 52-week range 36600-58600. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track HK inno.N's full fundamentals live
Get HK inno.N's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.